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ABSTRACT  
A novel, precise and accurate stability indicating RP-HPLC method was developed 
and validated for the simultaneous estimation of Metformin and Glipizide in 
combined pharmaceutical dosage form. Chromatographic separation was 
achieved on Microsorb-MV C18 column (250 × 4.6 mm, 5 μm) with UV detection 
at 257 nm. The mobile phase consists of acetate buffer (pH 4.0) and acetonitrile in 
the ratio of 60:40 v/v and at a flow rate of 1.0 mL/min. The method was linear 
over the concentration range of 60-140 μg/mL for Metformin and 10-50 μg/mL 
for Glipizide. The retention times for Metformin and Glipizide were found to be 
2.434 min and 5.710 min respectively. The mean percentage recoveries of 
Metformin and Glipizide were found to be 100.42% and 100.39% respectively. 
The method was validated and was successfully employed for the routine 
quantitative analysis of pharmaceutical formulations containing Metformin and 
Glipizide in combined pharmaceutical formulation.  
INTRODUCTION
Metformin (Fig. 1) is biguanide anti hyperglycemic 
agent used for treating non-insulin-dependent 
diabetes mellitus[1]. Chemically it is 1,1-
dimethylbiguanide. Metformin decreases hepatic 
glucose production, decreases intestinal absorption 
of glucose and improves insulin sensitivity by 
increasing peripheral glucose uptake and 
utilization[2,3]. 
Glipizide (Fig. 2) is a second-generation sulfonyl-
urea, is used to lower blood glucose in patients with 
diabetes mellitus type II[4]. Chemically it is N-[2-(4-
[(cyclohexylcarbamoyl) amino] sulfonyl} phenyl) 
ethyl]-5-methylpyrazine-2-carboxamide. Glipizide 
bind to ATP-sensitive potassium-channel receptors 
on the pancreatic cell surface, reducing potassium 
conductance and causing depolarization of the 
membrane. Depolarization stimulates calcium ion 
influx through voltage-sensitive calcium channels, 
raising intracellular concentrations of calcium ions, 
which induces the secretion, or exocytosis, of 
insulin[5,6]. 
Literature survey revealed that few HPLC 
methods[7-11] were reported for simultaneous 
estimation of Metformin and Glipizide in combined 
pharmaceutical dosage form. But no stability 
indicating HPLC method was reported. Hence the 
objective of this method is to develop and validate a 
simple, rapid, precise and accurate stability 
indicating RP-HPLC method in accordance with ICH 
guidelines[12,13] for the simultaneous estimation of 
Metformin and Glipizide in combined 
pharmaceutical dosage form. 
MATERIALS AND METHODS 
Materials  
Metformin and Glipizide pure drugs were obtained 
from Yarrow Chemicals, Mumbai, India. 
Combination of Metformin and Glipizide tablets 
(Glynase-MF Tablets) were obtained from local 
pharmacy store. Acetonitrile, glacial acetic acid, 
triethylamine and distilled water were obtained 
from Rankem Chemicals Ltd., Mumbai, India. 
Instrumentation  
The analysis of drugs was carried out on Agilent 
1260 infinity binary pump HPLC system on 
Microsorb-MV C18 column (250 × 4.6 mm, 5 μm). 
The instrument is equipped with auto injector with 
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20 µL sample loop. A 20 µL Hamilton syringe was 
used for injecting the samples. Data was analyzed 
by using Open Lab software. A double-beam 
Schimadzu UV-1800 UV-Visible spectrophotometer 
was used for measuring absorbance for Metformin 
and Glipizide solutions. Degassing of the mobile 
phase was done by using an ultrasonic bath 
sonicator. A Shimadzu balance was used for 
weighing the materials. 
Mobile phase  
A mobile phase consisting of mixture of acetate 
buffer (pH 4.0) and acetonitrile in the ratio of 60:40 
v/v was prepared. 
Preparation of standard stock and working 
solutions  
Standard stock solutions of Metformin and Glipizide 
were prepared by dissolving 50 mg of Metformin 
and Glipizide each dissolved in sufficient mobile 
phase. After that filtered the solution using 0.45 
micron filter paper and sonicated for 5 min and 
dilute to 50 mL with mobile phase. 1 mL from the 
resulting solution was transferred to 100 mL 
volumetric flask and diluted with mobile phase to 
obtain 100 µg/mL. Further dilutions of Metformin 
and Glipizide were made from stock solution using 
mobile phase. 
Preparation of sample stock and working 
solutions   
20 tablets (each tablet contains 500 mg of 
Metformin and 5 mg of Glipizide) were weighed and 
taken into a mortar and crushed to fine powder and 
uniformly mixed. Tablet stock solutions of 
Metformin and Glipizide were prepared by 
dissolving weight equivalent to 500 mg of 
Metformin and 5 mg of Glipizide and dissolved in 
sufficient mobile phase. After that filtered the 
solution using 0.45 μ syringe filter and sonicated for 
5 min and dilute to 100 mL with mobile phase. 
Further dilutions are prepared by adding 1 mL of 
stock solution to 10 mL of mobile phase. 
METHOD DEVELOPMENT  
Various trails were performed by using different 
mobile phases and based on peak parameters the 
chromatographic conditions (Table 1) were 
optimized and optimize chromatogram was shown 
in Fig. 3. 
METHOD VALIDATION 
System suitability parameters  
The system suitability parameters were determined 
by preparing standard solutions of Metformin (10 
µg/mL) and Glipizide (10 µg/mL) and the solutions 
were injected six times and the parameters like USP 
plate count, peak tailing and resolution were 
determined. All the system suitability parameters 
were within the range and satisfactory as per ICH 
guidelines. 
Specificity  
Specificity is the parameter used to check the 
interference in the optimized method. We should 
not find interfering peaks in blank, placebo, 
standard and sample at retention times of these 
drugs in this method. So this method was said to be 
specific.  
Linearity    
Five linear concentrations of Metformin (60-140 
µg/mL) and Glipizide (10-50 µg/mL) are prepared 
and injected. The results were furnished in Table 2 
and calibration curves were shown in Fig. 4 & 5. 
Precision  
Precision of method was studied by performing 
intra-day and inter-day precision. Intra-day 
precision (Table 3) and inter-day precision (Table 
4) was studied by injecting the 6 replicates of 
standard solution in a single day and six days. 
Calculate the %RSD and it should not be more than 
2.0.   
Accuracy  
The accuracy of the method was established by 
calculating percentage recovery of Metformin and 
Glipizide by the method of addition. Known amount 
of Metformin and Glipizide at 80%, 100% and 120% 
was added to a prequantified sample solution. The 
recovery studies (Table 5 & 6) were carried out in 
the tablet in triplicate each in the presence of 
placebo. The mean percentage recovery at each 
level was not less than 98% and not more than 
102%. 
Sensitivity  
Limit of detection (LOD) was calculated by standard 
deviation method. Limit of quantitation (LOQ) was 
calculated by standard deviation method. 
Degradation studies 
Acid degradation studies 
To 1mL of stock solution of Metformin and 
Glipizide, 1 mL of 2N hydrochloric acid was added 
and refluxed for 30 mins at 600C. The resultant 
solution was diluted to obtain 140 µg/mL & 50 
µg/mL solution and 20 µL solutions were injected 
into the system and the chromatograms were 
recorded to assess the stability of sample. 
Alkali egradation studies 
To 1 mL of stock solution of Metformin and 
Glipizide, 1 mL of 2N sodium hydroxide was added 
and refluxed for 30 mins at 600C. The resultant 
solution was diluted to obtain 500 µg/mL & 50 
µg/mL solution and 20 µL were injected into the 
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system and the chromatograms were recorded to 
assess the stability of sample. 
Oxidative degradation studies 
To 1 mL of stock solution of Metformin and 
Glipizide, 1 mL of 20% hydrogen peroxide was 
added separately. The solutions were kept for 30 
mins at 600C. For HPLC study the resultant solution 
was diluted to obtain 500 µg/mL & 50 µg/mL 
solution and 20 µL were injected into the system 
and the chromatograms were recorded to assess 
the stability of sample. 
Thermal degradation studies 
The standard drug solution was placed in oven at 
105°C for 6 hrs to study thermal degradation. For 
HPLC study the resultant solution was diluted to 
500 µg/mL & 50 µg/mL solution and 20 µL were 
injected into the system and the chromatograms 
were recorded to assess the stability of the sample. 
Neutral degradation studies 
Stress testing under neutral conditions was studied 
by refluxing the drug in water for 6 hours at a 
temperature of 60ºC. For HPLC study the resultant 
solution was diluted to 500 µg/mL & 50 µg/mL 
solution and 20 µL were injected into the system 
and the chromatograms were recorded to assess 
the stability of the sample. 
Degradation studies results of Metformin and 
Glipizide were tabulated in Table 7 & 8.  
 
 
  
Fig. 1: Structure of Metformin    Fig. 2: Structure of Glipizide   
 
Fig. 3: Optimized chromatogram of Metformin and Glipizide 
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Fig. 4: Calibration curve of Metformin   
 
 
Fig. 5: Calibration curve of Glipizide    
  
Table 1: Optimized chromatographic conditions 
Mobile phase Acetate buffer (pH 4.0):acetonitrile, 60:40 v/v  
Flow rate        1 mL/min  
Column   Microsorb-MV C18 (250 x 4.6  mm, 5 µm) 
Detector wave length    257 nm  
Column temperature 25°C  
Injection volume   20 µL  
Run time  8 min  
Diluent    Mobile phase 
Retention time Metformin: 2.434 min; Glipizide: 5.710 min 
Theoretical plates Metformin: 10205; Glipizde: 11067 
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Table 2: Linearity results for Metformin and Glipizide 
S. No. 
 
 
Concentration of 
Metformin (µg/mL) 
Peak area 
 
Concentration of 
Glipizide (µg/mL) 
       Peak area  
1 60 617813 10 202048 
2 80 672456 20 234061 
3 100 721269 30 269332 
4 120 786922 40 303857 
5 140 836059 50 337429 
Table 3: Intra-day precision results for Metformin and Glipizide 
    S. No. Metformin Peak area   Glipizide Peak area 
1 715899 219871 
2 716892 219396 
3 719354 218521 
4 720101 220945 
5 714879 219887 
6 717681 219680 
Mean 717467.7 219266.7 
Std. Dev. 2001.575 1368.826 
%RSD 0.27 0.62 
Table 4: Inter-day precision results for Metformin and Glipizide 
    S. No. Metformin Peak area   Glipizide Peak area 
1 719354 218521 
2 719575 220538 
3 714879 218938 
4 720046 220456 
5 719678 219871 
6 715899 219936 
Mean 718238.5 219710 
Std. Dev. 2241.843 815.9414 
%RSD 0.31 0.37 
Table 5: Accuracy results of Metformin 
Recovery 
level 
Amount taken 
(µg/mL) 
Area Average 
area 
Amount recovered 
(µg/mL) 
% 
Recovery 
Mean % 
Recovery 
80% 80 539581 541146 
 
80 
 
100.87 
 
 
 
 
 
100.42 
80 542834 
80 541024 
100% 100 596575 586936 
 
100 
 
100.22 
 100 564879 
100 599354 
120% 120 651605 654468 
 
120 100.17 
120 657164 
120 654636 
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Table 6: Accuracy results of Glipizide 
Table 7: Degradation data of Metformin 
S. No. Degradation 
condition 
Peak area % Assay Amount 
degraded % 
1 Acid 1383287 95.00 5.00 
2 Alkali 1087654 98.91 1.09 
3 Oxidative 1035678 97.16 2.84 
4 Thermal 1399673 96.12 3.88 
5 Neutral 1414765 97.85 2.15 
Table 8: Degradation data of Glipizide 
S. No. Degradation 
condition 
Peak area % Assay Amount 
degraded % 
1 Acid 283176 95.58 4.42 
2 Alkali 263176 96.12 3.88 
3 Oxidative 250591 95.98 4.02 
4 Thermal 321386 98.58 1.42 
5 Neutral 324896 97.22 2.78 
RESULTS & DISCUSSION 
A stability indicating RP-HPLC method was 
developed and validated for the simultaneous 
estimation of Metformin and Glipizide by using 
mobile phase consisting of acetate buffer (pH 4.0) 
and acetonitrile in the ratio of 60:40 v/v. The 
retention times for Metformin and Glipizide were 
found to be 2.434 min and 5.710 min respectively. 
The proposed method was validated as per ICH 
guidelines. The theoretical plates for Metformin and 
Glipizide were found to be 10205 and 11067 
respectively, which indicates the efficient 
performance of the column. Linearity range was 
found to be 60-140 µg/mL for Metformin and 10-50 
µg/mL for Glipizide. The %RSD values for intra-day 
precision values of Metformin and Glipizide were 
found to be 0.27 and 0.62 respectively. The %RSD 
values for inter-day precision values of Metformin 
and Glipizide were found to be 0.31 and 0.37 
respectively and hence the proposed method is 
precise. The mean percentage recoveries of 
Metformin and Glipizide were found to be 100.42% 
and 100.39% respectively and the method is found 
to be accurate. LOD for Metformin and Glipizide 
were found to be 0.287 µg/mL and 0.065 µg/mL 
respectively. LOQ for Metformin and Glipizide were 
found to be 0.870 µg/mL and 0.196 µg/mL 
respectively. Degradation studies were carried out 
in acid, alkali, oxidative, thermal and neutral 
stressed conditions. The results revealed that both 
the drugs are stable in described conditions. Thus it 
is evident that the described method can be 
adopted for routine estimation of Metformin and 
Glipizide in combined pharmaceutical dosage form. 
CONCLUSION 
The present method was proposed for the 
simultaneous estimation of Metformin and Glipizide 
by using RP-HPLC in tablet dosage form is found to 
be simple, rapid, accurate and precise. Retention 
times were decreased and that run time was 
Recovery 
level 
Amount taken 
(µg/mL) 
Area Average 
area 
Amount 
recovered 
(µg/mL) 
%Recovery Mean% 
Recovery 
80% 80 186679 187023 
 
20 
 
99.58 
 
 
 
 
 
100.39 
80 187409 
80 186981 
100% 100 201598 201314 
 
30 
 
100.80 
 100 200949 
100 201395 
120% 120 217865 218786 
 
40 
 
99.50 
 120 219340 
120 219153 
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decreased, so the method developed was simple 
and economical that can be applied in regular 
quality control tests in pharmaceutical industries.  
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